NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-226-2014-0-FR-01 ANTI-THYROGLOBULIN T CELL RECEPTORS FR EP 20208238.4 Issued
NCI E-226-2014-0-DE-01 ANTI-THYROGLOBULIN T CELL RECEPTORS DE EP 20208238.4 Issued
NCI E-226-2014-0-EP-09 ANTI-THYROGLOBULIN T CELL RECEPTORS EP DIV 20208238.4 Issued
NCI E-226-2014-0-GB-01 ANTI-THYROGLOBULIN T CELL RECEPTORS GB EP 20208238.4 Issued
NCATS E-128-2019-0-PCT-02 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME PCT PCT PCT/US2020/060848 Expired
NCATS E-128-2019-0-EP-05 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME EP National Stage 20824741.1 Pending
NCATS E-128-2019-0-JP-06 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME JP National Stage 2022-528974 Pending
NCATS E-128-2019-0-AU-03 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME AU National Stage 2020387937 Pending
NCATS E-128-2019-0-CA-04 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME CA National Stage 3161001 Pending
NCATS E-010-2022-0-US-01 Protein And Lipid Therapeutic Targets US 63/114,760 Abandoned
NIAID E-139-2006-0-BR-69 Development Of Dengue Virus Vaccine Components BR DIV BR122020023372-9 Issued
NIAID E-139-2006-0-BR-68 Development Of Dengue Virus Vaccine Components BR DIV BR122020023371-0 Pending
NCATS E-114-2018-0-AU-03 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS AU National Stage 2019271208 Issued
NCATS E-114-2018-0-JP-06 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS JP National Stage 2020-564095 Issued
NCI E-179-2019-0-PCT-02 PEGYLATED RECOMBINANT IMMUNOTOXINS PCT PCT PCT/US2020/060518 Expired
NCATS E-114-2018-0-US-07 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS US National Stage 17/055,256 Abandoned
NIAID E-018-2018-0-EP-08 CHIMERIC VECTORS EP National Stage 19729386.3 Pending
NICHD E-010-2021-0-US-01 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN US 63/113,428 Abandoned
NCI E-131-2018-0-US-04 Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy US CON 17/095,982 12037403 Issued PDF
NIAID E-089-2002-1-BR-90 Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in The 3'-UTR of Dengue Types 1,2,3, And 4, or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 BR DIV BR122020023165-3 Expired
NCI E-042-2014-0-AU-26 Chimeric Antigen Receptors Targeting CD-19 AU DIV 2020267211 Issued
NCATS E-095-2018-0-IN-05 QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS IN National Stage 202017049298 Abandoned
NCI E-213-2018-0-NZ-10 TRITERPENE AMINE DERIVATIVES NZ National Stage 769842 Issued
NCATS E-095-2018-0-US-06 QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS US National Stage 17/054,614 Abandoned
NCATS E-095-2018-0-BR-07 QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS BR National Stage BR112020023040-5 Abandoned
NHLBI E-197-2020-0-US-01 Single Cell Profiling Of Chromatin Occupancy And RNAs (scPCOR-seq) US 63/111,951 Abandoned
NCI E-192-2020-2-PCT-01 USE OF AGONISTS TO AUGMENT CAR T FUNCTION IN SOLID TUMORS PCT PCT COMB PCT/US2020/059751 Expired
NCI E-181-2017-0-HK-21 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS HK EP 62020019700.7 Pending
NINR E-062-2022-0-US-01 METHODS AND KITS FOR ASSESSING BRAIN INJURY US 63/111,333 Abandoned
NIDDK E-011-2021-0-US-01 CYCLOPENTANE FIT-PNAS: BRIGHT RNA SENSORS US 63/111,370 Abandoned
NCI E-075-2018-0-JP-03 HEXAMERIC TETRAHEDRAL RNA NANOSTRUCTURES JP National Stage 2020-563479 Issued
NCI E-075-2018-0-US-04 HEXAMERIC TETRAHEDRAL RNA NANOSTRUCTURES US National Stage 17/053,615 11666663 Issued PDF
NCI E-094-2017-0-AU-09 Fully Human Antibody Binders To Human Mesothelin For CAR-T Therapeutics Treatment AU DIV 2020264343 Issued
NHLBI E-134-2017-2-TW-02 ApoC-llA Mimetic Peptides That Antagonize ApoC-111 TW DIV 109138699 Pending
NCI E-060-2021-0-US-01 Antiviral Structurally-Stabilized Ebola Virus Peptides And Uses Thereof US 63/110,169 Abandoned
NCI E-231-2020-0-EP-01 METHOD OF SELECTING T CELLS WITH IMPROVED ANTI-CANCER ACTIVITY EP ORD 20306327.6 Pending
NCI E-183-2017-0-HK-14 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains HK EP 62020019504.3 Issued
NHLBI E-005-2021-0-US-01 MODIFIED NK CELLS WITH REDUCED CCR5 EXPRESSION AND METHODS OF THEIR USE US 63/109,707 Abandoned
NCI E-014-2021-0-US-01 Medi570 For The Treatment Of Lymphomas Expressing ICOS US 63/109,767 Abandoned
NCI E-094-2018-0-GB-01 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF GB EP 19726230.6 Issued
NCI E-094-2018-0-EP-06 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF EP National Stage 19726230.6 Issued
NIAID E-199-2020-0-US-01 HEPATITIS C VIRUS VACCINE TARGETING THE FUSION LOOP US 63/108,968 Abandoned
NIAID E-079-2018-0-US-03 ANTIBODIES AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION US National Stage 17/052,470 12084489 Issued PDF
NCI E-098-2018-0-CA-04 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR CA National Stage 3099106 Pending
NCI E-059-2013-0-JP-14 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor JP DIV 2020-182208 Issued
NCI E-098-2018-0-US-06 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR US National Stage 17/051,860 Pending
NCI E-282-2016-2-EP-36 Methods For Pre-conditioning Patients For Cell Therapy EP DIV 20204879.9 Pending
NCI E-150-2020-0-US-01 Synthetic Lethality-mediated Precision Oncology Via The Tumor Transcriptome US 63/107,737 Abandoned
NCI E-123-2018-0-US-04 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF US National Stage 17/051,574 12527870 Issued PDF
NIEHS E-125-2018-2-US-02 USE OF EPITHELIAL MEMBRANE PROTEIN 2 [EMP2] TARGETING AGENTS IN TREATING LUNG DISORDERS US National Stage 17/051,678 11890340 Issued PDF